Preventive Strategies for Chemotherapy-Induced Peripheral Neuropathy

Nielsen, Sebastian Werngreen; Herrstedt, Jørn

doi:10.1007/978-3-030-78663-2_4

Cited by 2 publications

(1 citation statement)

References 212 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Chemotherapy-induced peripheral neuropathy (CIPN) is an important long-term treatment side effect where symptoms severely affect health-related quality of life and inflict an estimated 37–84% of patients after end of treatment [ 2 , 3 , 4 ]. CIPN has a complex etiology [ 5 ] and a continuum of varied symptomatology with no clear diagnostic criteria or cutoffs [ 6 ], hampering early screening and management of CIPN. Since CIPN cannot be prevented, it has been managed with treatment alterations, guided by clinician-graded symptom severity such as the National Clinical Institute—Common Terminology Criteria for Adverse Events (NCI-CTCAE) [ 7 ].…”

Section: Introductionmentioning

confidence: 99%

Addressing Chemotherapy-Induced Peripheral Neuropathy Using Multi-Frequency Vibrometry and Patient-Reported Outcomes

Nielsen

Lindberg

Ruhlmann

et al. 2022

JCM

Self Cite

View full text Add to dashboard Cite

(1) The study evaluated correlations between multi-frequency vibrometry (MF-V) and the measure of chemotherapy-induced peripheral neuropathy developed by the European Organization for the Research and Treatment of Cancer (CIPN18). (2) Patients with cancer scheduled to undergo treatment with capecitabine and oxaliplatin (CAPOX) or carboplatin and paclitaxel (Carbo-Tax) were recruited in a prospective, observational study with MF-V and the CIPN18 from baseline to one year after end of treatment. (3) The study recruited 31 evaluable patients. All MF-V measurements correlated significantly with the CIPN18 scores (r = 0.25–0.48, p > 0.003), with a low frequency (32 Hz) from metatarsals showing the best correlation coefficients (0.059 Z-score per CIPN18 point change, r = 0.48, CI-95 = [0.32; 0.60], p > 0.0001). The largest change in MF-V scores from baseline was seen in low-frequency VPTs taken from metatarsals at 8 Hz three months after end of treatment (from −0.26, CI-95 [−0.85, 0.38] to 1.15, CI-95 [0.53, 1.84]) for patients treated with oxaliplatin and at 32 Hz one year after end of treatment (from 0.09, CI-95 [−0.56, 0.77] to 0.88, CI-95 [0.34, 1.47]) for patients treated with paclitaxel. (4) Low-frequency vibration perception thresholds (8 and 32 Hz) correlated better with CIPN18 scores than high-frequency ones (128 and 250 Hz). If validated, this finding will advance CIPN pathophysiological understanding and inform the development of assessment methods.

show abstract